CoChat

Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer

Open access

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Neutropenia is a common side effect associated with nab-paclitaxel gemcitabine (Nab-Gem) therapy. We retrospectively investigated the association between neutropenia induced by first-line Nab-Gem and survival in metastatic pancreatic carcinoma patients. Metastatic pancreatic patients treated with first-line Nab-Gem were included in this retrospective analysis. Neutropenia was categorized using the National Cancer Institute Common Toxicity Criteria scale. Outcome measures were overall survival (OS), progression-free survival (PFS) and response rate. 115 patients were analyzed. Median PFS was 7 months (95% CI 5–8) for patients with grade ≥ 3 neutropenia and 6 months (95% CI 5–6) for patients with grade < 3 neutropenia [p = 0.08; hazard ratio (HR 0.68)]. Median OS was 13 months (95% CI 10–18) for patients with grade ≥ 3 neutropenia and 10 months (95% CI 8–13) for patients with grade < 3 neutropenia (p = 0.04; HR 0.44). In multivariate analysis, the occurrence of grade ≥ 3 neutropenia showed a statistically significant association with OS (HR 0.62; 95% CI 0.09–0.86; p = 0.05). Nab-Gem-induced neutropenia is associated with longer survival in metastatic pancreatic cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-020-76465-9

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Estimated PFS for Nab-Gem in patients with grade ≥ 3 neutropenia (red) or without (blue).
Figure 1 Estimated PFS for Nab-Gem in patients with grade ≥ 3 neutropenia (red) or without (blue).CC BY · PubMed Central
Figure 2 Estimated OS for Nab-Gem in patients with grade ≥ 3 neutropenia (red) or without (blue).
Figure 2 Estimated OS for Nab-Gem in patients with grade ≥ 3 neutropenia (red) or without (blue).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 16

Metadata

Authors
Roviello, G., Ramello, M., Catalano, M., D’Angelo, A., Conca, R., Gasperoni, S., Dreoni, L., Petrioli, R., Ianza, A., Nobili, S., Aieta, M., & Mini, E.
Affiliations
  • University of Florence (IT)
  • University of Trieste (IT)
  • University of Bath (GB)
  • Centro di Riferimento Oncologico della Basilicata (IT)
  • Azienda Ospedaliero-Universitaria Careggi (IT)
  • University of Siena (IT)
Corresponding author
Roviello, Giandomenico
Venue
Scientific Reports
Published
2020-11-06
Volume
10
Issue
1
Pages
19281-19281
ISSN
2045-2322 (ISSN-L)
OpenAlex
W3096053571
Cited by
16
References
26
Citations by year
2025: 3 · 2024: 5 · 2023: 3 · 2022: 3 · 2021: 2
FWCI
0.72
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Florence Research (University of Florence) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Keywords
neutropenia, nab-paclitaxel, gemcitabine, metastatic pancreatic cancer, first-line chemotherapy, chemotherapy toxicity, overall survival, progression-free survival, treatment response
MeSH terms
Gemcitabine, Aged, Aged, 80 and over, Albumins, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Neutropenia, Pancreatic Neoplasms, Retrospective Studies, Survival Rate, Paclitaxel, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. https://app.cochat.ai/papers/10.1038/s41598-020-76465-9
The paper
Roviello, G., Ramello, M., Catalano, M., D’Angelo, A., Conca, R., Gasperoni, S., Dreoni, L., Petrioli, R., Ianza, A., Nobili, S., Aieta, M., & Mini, E. (2020). Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. Scientific Reports. https://doi.org/10.1038/s41598-020-76465-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.